A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

NCT02714218 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

387

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

BIOLOGICAL: Nivolumab 3 mg/kg IV
BIOLOGICAL: Ipilimumab 1 mg/kg IV
BIOLOGICAL: Nivolumab 1 mg/kg IV
BIOLOGICAL: Ipilimumab 3 mg/kg IV
BIOLOGICAL: Nivolumab 6 mg/kg IV

Sponsor

Bristol-Myers Squibb